scispace - formally typeset
M

Melissa Assel

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  83
Citations -  2166

Melissa Assel is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 21, co-authored 68 publications receiving 1524 citations.

Papers
More filters
Journal ArticleDOI

Copy number alteration burden predicts prostate cancer relapse

TL;DR: It is demonstrated that copy number alteration (CNA) burden, a measure of the fraction of a tumor genome that is copy number altered, is prognostic for recurrence and metastasis and can be measured in diagnostic needle biopsies using low-input whole-genome sequencing, setting the stage for studies of prognostic impact in conservatively treated cohorts.
Journal ArticleDOI

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

Elizabeth Bancroft, +115 more
- 01 Sep 2014 - 
TL;DR: The IMPACT screening network is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations.
Journal ArticleDOI

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer

TL;DR: Two blood tests, the Prostate Health Index and the four-kallikrein panel, performed similarly and could both aid in decision making among Swedish men undergoing a prostate biopsy and similarly improved discrimination when predicting PCa and high-grade PCa.
Journal ArticleDOI

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Elizabeth Page, +150 more
- 01 Dec 2019 - 
TL;DR: After 3 yr of prostate-specific antigen (PSA) testing, it is demonstrated that after 3’yr of screening, more serious prostate cancers are detected in men with BRCA2 mutations than in those without these mutations.